ViaCell and Centocor seal cardiac deal
This article was originally published in Clinica
Executive Summary
ViaCell has teamed up with Johnson & Johnson (J&J) firm Centocor to assess in preclinical trials its proprietary cord blood-derived multi-potent stem cells as a treatment for cardiac disease.